{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:16:40Z","timestamp":1793506600272,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Science and Technology Foundation","doi-asserted-by":"publisher","award":["2023A03J0701"],"award-info":[{"award-number":["2023A03J0701"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundamental Research Funds for the Central Universities, Sun Yat-sen University","award":["24xkjc035"],"award-info":[{"award-number":["24xkjc035"]}]},{"name":"Guangzhou Key Laboratory of Precise Diagnosis and Treatment of Biliary Tract Cancer","award":["202201020375"],"award-info":[{"award-number":["202201020375"]}]},{"name":"Guangzhou Key Laboratory of Precise Diagnosis and Treatment of Biliary Tract Cancer","award":["[2013]163"],"award-info":[{"award-number":["[2013]163"]}]},{"name":"Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology","award":["KLB09001"],"award-info":[{"award-number":["KLB09001"]}]},{"DOI":"10.13039\/501100013183","name":"Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013183","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangdong Science and Technology Department","award":["2015B050501004"],"award-info":[{"award-number":["2015B050501004"]}]},{"name":"Guangdong Science and Technology Department","award":["2017B030314026"],"award-info":[{"award-number":["2017B030314026"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The efficacy and safety of chemotherapy combined with programmed cell death protein-1 (PD-1) inhibitors in postoperative adjuvant therapy of pancreatobiliary subtype ampullary adenocarcinoma (AAC) are uncertain. This study aims to evaluate the effect of such treatment on the survival of this patient population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively collected patients with pancreatobiliary subtype AAC who underwent surgical treatment at the Sun Yat-sen Memorial Hospital from January 2018 to December 2022. Patients with high-risk recurrence factors after surgery were divided into surgery alone group, adjuvant chemotherapy group, and adjuvant chemoimmunotherapy group. The Kaplan\u2013Meier method was used to plot survival curves, and the Log-Rank method was used to compare the differences in overall survival (OS) and recurrence-free survival (RFS) between groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 71 people were enrolled, including 24 patients received surgery alone, 31 patients received adjuvant chemotherapy, and 16 patients received adjuvant chemoimmunotherapy. The median time of clinical follow-up was 17.8 [IQR 8.3-28.4] months. The 1-year OS rates of the surgery alone group, adjuvant chemotherapy group, and adjuvant chemoimmunotherapy were 41.7%, 71.0%, and 93.3%, respectively. The 2-year OS rates were 28.6%, 47.7%, and 84.0%, respectively. The median OS was 6.8 months and 22.1 months, but the adjuvant chemoimmunotherapy group did not reach (P\u2005=\u2005.0002). The median RFS was 4.7 months, 15.7 months, and 14.8 months, respectively, but the differences were not statistically significant (P\u2005=\u2005.0613). Univariate and multivariate Cox analysis results showed that tumor size &amp;gt;2.3\u00a0cm (HR\u2005=\u20052.06, 95% CI, 1.06-4.04; P\u2005=\u2005.034) and the treatment regimen were independent factors affecting prognosis, compared to surgery alone and adjuvant chemotherapy (HR\u2005=\u20050.521, 95% CI, 0.26-1.04; P\u2005=\u2005.065), adjuvant chemoimmunotherapy (HR\u2005=\u20050.106, 95% CI, 0.02-0.47; P\u2005=\u2005.003) significantly improves patient survival. There was no statistically significant difference in any complications between the 3 groups (P &amp;gt; .05). Compared with the adjuvant chemotherapy group, patients in the adjuvant chemoimmunotherapy group are more likely to experience hypothyroidism (P\u2005=\u2005.044) and pruritus (P\u2005=\u2005.022). There is no statistically significant difference in other AEs between the 2 groups (P &amp;gt; .05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Compared with surgery alone or adjuvant chemotherapy, patients with pancreatobiliary subtype AAC who received adjuvant chemoimmunotherapy showed better OS, and the drug-related toxicity was acceptable.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf104","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:25:36Z","timestamp":1749047136000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with pancreatobiliary subtype ampullary adenocarcinoma"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2864-2480","authenticated-orcid":false,"given":"Jiahao","family":"Xue","sequence":"first","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou 510120 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjun","family":"Lu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou 510120 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangde","family":"Shi","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou 510120 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenglong","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou 510120 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Ye","sequence":"additional","affiliation":[{"name":"Clinical Research Design Division, Sun Yat-sen Memorial Hospital , Guangzhou 510120 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibin","family":"Tang","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou 510120 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhuan","family":"Yu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou 510120 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation and Department of Biliary-Pancreatic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou 510120 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"2025060410253303600_CIT0001","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jamcollsurg.2005.08.002","article-title":"Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma","volume":"202","author":"Kim","year":"2006","journal-title":"J Am Coll Surg"},{"key":"2025060410253303600_CIT0002","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.3390\/curroncol30070507","article-title":"Ampullary cancer: histological subtypes, markers, and clinical behaviour-state of the art and perspectives","volume":"30","author":"Nappo","year":"2023","journal-title":"Curr Oncol"},{"key":"2025060410253303600_CIT0003","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.asjsur.2020.03.007","article-title":"Prognostic factors and benefits of adjuvant therapy for ampullary cancer following pancreatoduodenectomy: a systematic review and meta-analysis","volume":"43","author":"Zhou","year":"2020","journal-title":"Asian J Surg"},{"key":"2025060410253303600_CIT0004","doi-asserted-by":"publisher","first-page":"85","DOI":"10.23736\/S1121-421X.18.02543-6","article-title":"Demographics, tumor characteristics, treatment, and clinical outcomes of patients with ampullary cancer: a surveillance, epidemiology, and end results (seer) cohort study","volume":"65","author":"Ramai","year":"2019","journal-title":"Minerva Gastroenterol Dietol"},{"key":"2025060410253303600_CIT0005","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.ejso.2021.02.028","article-title":"A population-based study on incidence, treatment, and survival in ampullary cancer in the netherlands","volume":"47","author":"de Jong","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"2025060410253303600_CIT0006","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1245\/s10434-008-9886-1","article-title":"Survival after resection of ampullary carcinoma: a national population-based study","volume":"15","author":"O\u2019Connell","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"2025060410253303600_CIT0007","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamasurg.2019.1171","article-title":"Adjuvant therapy for ampullary cancer","volume":"154","author":"Ko","year":"2019","journal-title":"JAMA Surg"},{"key":"2025060410253303600_CIT0008","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamasurg.2019.1170","article-title":"Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma","volume":"154","author":"Ecker","year":"2019","journal-title":"JAMA Surg"},{"key":"2025060410253303600_CIT0009","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s11605-017-3624-6","article-title":"Association of adjuvant therapy with improved survival in ampullary cancer: a national cohort study","volume":"22","author":"Nassour","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"2025060410253303600_CIT0010","doi-asserted-by":"publisher","first-page":"753","DOI":"10.6004\/jnccn.2023.0034","article-title":"Ampullary adenocarcinoma, version 1.2023, nccn clinical practice guidelines in oncology","volume":"21","author":"Chiorean","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2025060410253303600_CIT0011","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2025060410253303600_CIT0012","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase ii keynote-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025060410253303600_CIT0013","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.21.01015","article-title":"First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: the phase ii checkmate 142 study","volume":"40","author":"Lenz","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025060410253303600_CIT0014","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"2025060410253303600_CIT0015","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.surg.2005.05.001","article-title":"Postoperative pancreatic fistula: an international study group (isgpf) definition","volume":"138","author":"Bassi","year":"2005","journal-title":"Surgery"},{"key":"2025060410253303600_CIT0016","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.surg.2010.12.002","article-title":"Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the international study group of liver surgery","volume":"149","author":"Koch","year":"2011","journal-title":"Surgery"},{"key":"2025060410253303600_CIT0017","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.surg.2007.02.001","article-title":"Postpancreatectomy hemorrhage (PPH): an international study group of pancreatic surgery (ISGPS) definition","volume":"142","author":"Wente","year":"2007","journal-title":"Surgery"},{"key":"2025060410253303600_CIT0018","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/EJA.0000000000000118","article-title":"Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European perioperative clinical outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures","volume":"32","author":"Jammer","year":"2015","journal-title":"Eur J Anaesthesiol"},{"key":"2025060410253303600_CIT0019","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the espac-3 periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"key":"2025060410253303600_CIT0020","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"2025060410253303600_CIT0021","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/bjs.11555","article-title":"Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study","volume":"107","author":"Moekotte","year":"2020","journal-title":"Br J Surg"},{"key":"2025060410253303600_CIT0022","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.pan.2020.01.009","article-title":"Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy \u2013 a multicenter cohort study","volume":"20","author":"Bolm","year":"2020","journal-title":"Pancreatology"},{"key":"2025060410253303600_CIT0023","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ijrobp.2006.04.018","article-title":"Adjuvant therapy for ampullary carcinomas: the mayo clinic experience","volume":"66","author":"Bhatia","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025060410253303600_CIT0024","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1007\/s12094-018-1849-9","article-title":"Adjuvant radiotherapy following pancreaticoduodenectomy for ampullary adenocarcinoma improves survival in node-positive patients: a propensity score analysis","volume":"20","author":"Kamarajah","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"2025060410253303600_CIT0025","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1748-717X-6-126","article-title":"Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins hospital-mayo clinic collaborative study","volume":"6","author":"Narang","year":"2011","journal-title":"Radiat Oncol"},{"key":"2025060410253303600_CIT0026","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s11605-009-1080-7","article-title":"Clinicopathologic analysis of ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis","volume":"14","author":"Winter","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"2025060410253303600_CIT0027","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1200\/jco.2016.34.15_suppl.9518","article-title":"Overall survival in patients with advanced melanoma (mel) who discontinued treatment with nivolumab (nivo) plus ipilimumab (ipi) due to toxicity in a phase ii trial (checkmate 069)","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025060410253303600_CIT0028","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s12328-021-01396-5","article-title":"Durable response after discontinuation of pembrolizumab therapy for intrahepatic cholangiocarcinoma: a case report","volume":"14","author":"Eguchi","year":"2021","journal-title":"Clin J Gastroenterol"},{"key":"2025060410253303600_CIT0029","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jconrel.2024.01.057","article-title":"Enhancing cell pyroptosis with biomimetic nanoparticles for melanoma chemo-immunotherapy","volume":"367","author":"Sun","year":"2024","journal-title":"J Control Release"},{"key":"2025060410253303600_CIT0030","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00262-022-03362-7","article-title":"Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with perihilar cholangiocarcinoma at high risk of recurrence","volume":"72","author":"Liu","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2025060410253303600_CIT0031","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label keynote-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025060410253303600_CIT0032","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2105\/ajph.94.3.361","article-title":"Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the trend statement","volume":"94","author":"Des Jarlais","year":"2004","journal-title":"Am J Public Health"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf104\/63435397\/oyaf104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/6\/oyaf104\/63435397\/oyaf104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:25:37Z","timestamp":1749047137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf104\/8156674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,4]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf104","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"oyaf104"}}